amifampridine phosphate (firdapse) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA

Active Ingredient History

  • Now
Amifampridine (Firdapse), currently approved in the European Union, is the first and only approved drug for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in adults, a rare autoimmune disease with the primary symptoms of muscle weakness. In LEMS, the body’s own immune system attacks connections between nerves and muscles and disrupts the ability of nerve cells to send signals to muscle cells. Amifampridine blocks voltage-dependent potassium channels, thereby prolonging pre-synaptic cell membrane depolarization. Prolonging the action potential enhances the transport of calcium into the nerve ending. The resulting increase in intracellular calcium concentrations facilitates exocytosis of acetylcholine containing vesicles, which in turn enhances neuromuscular transmission. Amifampridine phosphate has been granted Orphan Drug Designation and Breakthrough Therapy designation by the FDA for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS).   NCATS

More Chemistry

Drug Pricing (per unit)

United States

$56.8892 - $127.5129
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

1-(diethylaminopropyl)-4-phenylpiperazine | 3,4-dap | 3,4-dapp | 3,4 diaminopyridine | 3,4-diaminopyridine | 3,4-diammoniopyridinium | 4-dap | 4-diaminopyridine | amifampridin | amifampridine | amifampridine phosphate | dap | dapp | diaminopyridine | firdapse | pyridine-3,4-diamine


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue